Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.75% -0.05% 1.694B 1.629M
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
2.75% 46.00% 591.80M Upgrade

Basic Info

Investment Strategy
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Alternative Harvest Index. The index is concentrated in the Pharmaceuticals, Biotechnology and Life Sciences group of industries and tracks the performance of the exchange-listed common stock (or corresponding ADRs or GDRs) of companies across the globe. The fund will invest at least 80% of its total assets, exclusive of collateral held from securities lending, in the component securities of the index and in ADRs and GDRs based on the component securities in the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Miscellaneous Sector
Category Index Morningstar US Market TR USD
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name ETFMG
Prospectus Benchmark Index
Prime Alternative Harvest NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Devin Ryder 2.90 yrs
Samuel Masucci 2.90 yrs
Donal Bishnoi 1.50 yrs
Frank Vallario 1.50 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 23
591.80M
-2.143M Category Low
4.417B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of March 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of April 16, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
13.15%
39.37%
-21.77%
-28.52%
-11.63%
47.10%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
10.27%
-1.25%
-8.76%
-43.23%
54.39%
-25.66%
66.53%
233.9%
-16.81%
-8.19%
2.34%
12.42%
30.52%
-12.48%
36.45%
51.02%
0.10%
-3.16%
-6.21%
-2.69%
32.33%
-12.37%
42.65%
184.0%
-6.88%
-4.78%
3.82%
-16.91%
21.48%
-9.02%
44.35%
141.8%
-15.65%
As of April 16, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-16-21) 2.75%
30-Day SEC Yield (4-1-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 16, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 16, 2021

Asset Allocation

As of April 16, 2021.
Type % Net % Long % Short
Cash 0.88% Upgrade Upgrade
Stock 99.12% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
GW Pharmaceuticals PLC ADR 11.29% 218.90 0.04%
Aphria Inc 8.36% 17.69 4.06%
GrowGeneration Corp 5.88% 47.10 0.64%
Tilray Inc 5.29% 17.20 1.53%
Canopy Growth Corp 5.26% 34.76 1.22%
Cronos Group Inc 4.57% 10.43 2.56%
Schweitzer-Mauduit International Inc 4.39% 49.74 0.26%
Altria Group Inc 4.13% 52.31 1.36%
Vector Group Ltd 4.10% 14.49 0.00%
Philip Morris International Inc 3.85% 92.91 1.18%

Basic Info

Investment Strategy
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Alternative Harvest Index. The index is concentrated in the Pharmaceuticals, Biotechnology and Life Sciences group of industries and tracks the performance of the exchange-listed common stock (or corresponding ADRs or GDRs) of companies across the globe. The fund will invest at least 80% of its total assets, exclusive of collateral held from securities lending, in the component securities of the index and in ADRs and GDRs based on the component securities in the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Miscellaneous Sector
Category Index Morningstar US Market TR USD
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name ETFMG
Prospectus Benchmark Index
Prime Alternative Harvest NR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Devin Ryder 2.90 yrs
Samuel Masucci 2.90 yrs
Donal Bishnoi 1.50 yrs
Frank Vallario 1.50 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-16-21) 2.75%
30-Day SEC Yield (4-1-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of April 16, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of April 16, 2021

Fund Details

Key Dates
Inception Date 12/3/2015
Last Annual Report Date 9/30/2020
Last Prospectus Date 1/29/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No